CHO cell line selection for development of stable cell line producing recombinant human follicle-stimulating hormone


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Follicle-stimulating hormone (FSH) is one of the most important hormones of reproductive system and it is widely used as a treatment in an assisted reproductive technology. Choice of productive cell line for recombinant human FSH (rhFSH) protein production is the major issue of biotechnological process. Study objective. The aim of the study was to generate stable cell lines for rhFSH production using different parental CHO cell lines and compare their characteristics. Material and methods. Two CHO suspension parental cell lines were used for stable cell line generation - CHO-K1 and CHO-DXB 11 adapted to suspension conditions. Cell count and viability were analyzed by trypan blue exclusion method. RhFSH concentration was measured by ELISA, protein identity was confirmed by western blot analysis. Results. Four clones generated from CHO-DXB 11 cell line were selected after 3 steps - pool selection, clone selection and methotrexate amplification. Productivity during 6 days of cultivation for the most productive clone CHO-FSH 11/24 was 7,1±0,6 mg/l. Three clones were chosen after transfection and cell cloning of CHO-K1 cells transfected with plasmids containing of FSH α- and β-chains sequences. The highest productivity was detected for CHO-FSH91 clone and it was 10,8±0,9 mg/l. Molecular weight of rhFSH was identical for rhFSH purified from cell culture of optimal clones and commercial preparation Gonal-F (Merck Serono).

Full Text

Restricted Access

About the authors

V. S Monakhova

FGUP «State Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency

Email: v.s.monakhova@hpb.spb.ru

N. V Pigareva

FGUP «State Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency

A. S Simbirtsev

FGUP «State Research Institute of Highly Pure Biopreparations» of the Federal Biomedical Agency

References

  1. Latash W.D., Karande V.C., Klipstein S. The development of recombinant follicle stimulating hormone (rFSH) for use in the treatment of infertility: new solutions to old challenges. Reviews in Gynaecological Practice. 2004; 4:203-210.
  2. Keene J.L., Matzuk M.M. et al. Expression of biologically active human follitropin in chinese hamster ovary cells. The Journal of Biological Chemistry. 1989; 264(9):4769-4775.
  3. Olijve W., Boer W. et al. Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®). Molecular Human Reproduction. 1996; 2(5):371-382.
  4. NA K.H., Seo K.S., Kim W.B., Kim S.-Ch., Lee S.-H., Lee K.S. Purification and Characterization of Recombinant Human Follicle Stimulating Hormone Produced by Chinese Hamster Ovary Cells. J. Microbiol. Biotechnol. 2005; 15(2):395-402.
  5. Kim D.J., SeokS.-H., BaekM.-W., Lee H.-Y., Juhn J.-H., Lee S. et al. Highly expressed recombinant human follicle-stimulating hormone from Chinese hamster ovary cells grown in serum-free medium and its effect on induction of folliculogenesis and ovulation. 2010; 93(8):2652-2660.
  6. Патент № 2615447 (РФ). Синтетическая ДНК, кодирующая интерлейкин-7 человека, содержащий ее экспрессионный вектор (варианты), штамм-продуцент интерлейкина-7 человека и способ получения интерлейкина-7 человека. Ищенко А.М., Кудлинг Т.В., Петров А.В., Пигарева Н.В., Протасов Е.А., Симбирцев А.С. 2017.
  7. Патент № 2616273 (РФ). Синтетическая ДНК, кодирующая антимюллеров гормон человека, содержащий ее экспрессионный вектор pTVK4pu/MISOPT и штамм клеток яичников китайского хомячка CHO-MIS - продуцент рекомбинантного антимюллерового гормона человека. Петров А.В., Карасев М.М., Кудлинг Т.В., Пигарева Н.В., Сергеева В.Е., Трофимов А.В., Ищенко А.М., ГорбуновА А.,Вахрушев А.В., Симбирцев А.С. 2017.
  8. Betts Z., Dickson A.J. Ubiquitous Chromatin Opening Elements (UCOEs) effect on transgene position and expression stability in CHO cells following methotrexate (MTX) amplification. Biotechnol J. 2016; 11(4):554-641.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies